Anika Therapeutics | ANIK - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Abbott USD 68M 26M 2026-03
Agenus USD 16.02M 2.85M 2025-12
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Anika Therapeutics 179.39M 556.84M 2026-03
Arrowhead Research USD 22.5M 811K 2025-12
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Halozyme Therapeutics USD 5.51M 597K 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 20.08M 517K 2026-03
Integra LifeSciences USD 22.46M 1.21M 2026-03
Intrexon USD 2K 5K 2024-06
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Merit Medical Systems USD 6.53M 162K 2026-03
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 178M 203M 2026-03
Smith & Nephew USD 69M 1000K 2025-12
Stryker USD 46.29B 45.68B 2026-03
Surmodics USD 884K 5K 2024-09
Veracyte USD 2K 1000 2023-12
Xencor USD 4.7M 2.65M 2026-03
Zimmer Biomet Holdings USD 68.8M 3.1M 2026-03